Ferroptosis biomarkers predict tumor mutation burden's impact on prognosis in HER2-positive breast cancer

Figure 5 The four ferroptosis-related prognostic gene signature models for predicting 3-, 5-, and 8-year overall survival in HER2+ breast cancer patients. A: Independent risk factors were used to build a risk estimation nomogram to predict the probability of overall survival in HER2+ breast cancer patients; B: Calibration plots for 3-, 5-, and 8-year survival probabilities in the TCGA cohort; C: Restricted mean survival time Curve in the TCGA cohort. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. OS: Overall survival; RMS time: Restricted mean survival time.